• LAST PRICE
    1.9700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.8500/ 1
  • Ask / Lots
    2.1100/ 5
  • Open / Previous Close
    --- / 1.9700
  • Day Range
    ---
  • 52 Week Range
    Low 1.5000
    High 12.6800
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.09
TimeVolumeIXHL
09:32 ET3142.06
09:44 ET1502.09
10:31 ET4202.0702
10:38 ET1502.075
10:45 ET1002.05
11:21 ET19002.04
11:52 ET2112.04
12:24 ET1002.05
12:26 ET2002.045
12:28 ET1002.055
12:37 ET2002.05
01:47 ET3002.04
02:00 ET2002.07
02:23 ET1002.03
02:54 ET5012.0345
03:03 ET6002.0101
03:24 ET1002.0199
03:32 ET36002.0101
03:35 ET11132.01
03:37 ET18002
03:39 ET4141.96
03:55 ET26001.96
04:00 ET6891.97
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIXHL
Incannex Healthcare Inc
34.8M
-1.4x
---
United StatesBQST
BioQuest Corp
10.9M
-19.6x
---
United StatesTXMD
TherapeuticsMD Inc
15.3M
-3.8x
---
United StatesTLPH
Talphera Inc
11.9M
-1.0x
---
United StatesSYBE
SYBLEU Inc
5.5M
-1.9x
---
United StatesSNBH
Sentient Brands Holdings Inc
5.1M
-4.1x
---
As of 2024-11-22

Company Information

Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.

Contact Information

Headquarters
18 East 50th Street, 5th FloorNEW YORK, NY, United States 10022
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Troy Valentine
President, Chief Executive Officer, Executive Director
Joel Latham
Chief Financial Officer, Controller, Treasurer, Company Secretary
Joseph Swan
Chief Technology Officer
Lekhram Changoer
Chief Medical Officer
Luigi Barbato

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$34.8M
Revenue (TTM)
$86.0K
Shares Outstanding
17.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.40
Book Value
$0.71
P/E Ratio
-1.4x
Price/Sales (TTM)
404.1
Price/Cash Flow (TTM)
---
Operating Margin
-36,506.98%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.